Tuberculosis in England

2019 report: Executive Summary

Presenting data to end of 2018
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.gov.uk/phe
Twitter: @PHE_uk
Facebook: www.facebook.com/PublicHealthEngland

Prepared by: Tuberculosis Unit, National Infection Service, PHE
For queries relating to this document, please contact: tbsection@phe.gov.uk

© Crown copyright 2019
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published July 2019
PHE publications
gateway number: GW-594

PHE supports the UN
Sustainable Development Goals
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contents</td>
<td>3</td>
</tr>
<tr>
<td>Background</td>
<td>4</td>
</tr>
<tr>
<td>Executive summary</td>
<td>5</td>
</tr>
<tr>
<td>TB notifications and incidence</td>
<td>6</td>
</tr>
<tr>
<td>Laboratory confirmation of TB</td>
<td>6</td>
</tr>
<tr>
<td>TB Transmission</td>
<td>7</td>
</tr>
<tr>
<td>Delay from symptom onset to treatment start</td>
<td>7</td>
</tr>
<tr>
<td>TB outcomes in the drug sensitive cohort</td>
<td>8</td>
</tr>
<tr>
<td>Drug resistant TB and outcomes in the drug resistant cohort</td>
<td>8</td>
</tr>
<tr>
<td>TB in under-served populations</td>
<td>9</td>
</tr>
<tr>
<td>TB-HIV co-infection and HIV testing among TB cases</td>
<td>10</td>
</tr>
<tr>
<td>BCG vaccination</td>
<td>10</td>
</tr>
<tr>
<td>Latent TB infection testing and treatment</td>
<td>10</td>
</tr>
<tr>
<td>United Kingdom TB pre-entry screening programme</td>
<td>11</td>
</tr>
<tr>
<td>Conclusions</td>
<td>11</td>
</tr>
<tr>
<td>References</td>
<td>12</td>
</tr>
</tbody>
</table>
Background

This is an Executive Summary of data on tuberculosis (TB) notifications made to the Enhanced Tuberculosis Surveillance system (ETS) in England to the end of 2018. Detailed results for 2018 are published in the annual report ‘Tuberculosis in England: 2019 report’, available here.

This summary includes the main points of note in the report supported by important figures and aims to provide a readily accessible summary for individuals and organisations working in the field of TB.
Executive summary

The number of people with TB in England has fallen from a peak of 8,280 in 2011 to 4,655 in 2018 – a reduction of approximately 44%. The incidence of TB in 2018 (8.3 per 100,000 population) was the lowest TB rate ever recorded in England. However, if we are to reach the World Health Organisation’s (WHO) End TB Strategy target of a 90% reduction in new notifications by 2035 [1], considerable efforts and new, innovative approaches will be needed to eliminate TB in England. Some of the important challenges include:

- understanding that variation in TB incidence and patient profiles faced across the country means no single approach will be sufficient – even within a single city or area
- the need to focus on addressing the needs of people with social risk factors (SRFs) such as alcohol misuse, drug misuse, homelessness and/or imprisonment
- focusing on reducing transmission of TB in the UK using techniques such as Whole Genome Sequencing (WGS) to better understand transmission pathways and networks
- ensuring excellence in MDR-TB management including through referral of people with MDR-TB to the British Thoracic Society MDR-TB Clinical Advice Service
- maintaining latent TB infection (LTBI) testing and treatment to prevent reactivation of TB and further transmission
- build on the work of the Collaborative TB Strategy for England 2015-2020 by developing a 5-year action beyond 2020 to further drive down TB numbers

It is also important to recognise the work that has been undertaken to date and which forms a good foundation for future work:

1. The well developed and mature relationships developed by local TB Control Boards (TBCBs) that enable the multi-disciplinary approach will continue to be essential to addressing the complex problems TB control presents.

2. As part of development of the new National TB Surveillance System (NTBS), a suite of reports has been released that allow local teams to have improved access to data. These reports can be used to monitor progress, assess the effectiveness of local interventions and identify problems at an early stage. Further work to replace the legacy systems (ETS and LTBR) will introduce functionality to streamline the process of notifying new TB patients.
This summary now presents the main points of note from the annual ‘Tuberculosis in England: 2019 report’, supported by important figures, in a readily accessible summary for individuals and organisations working in the field of TB.

**TB notifications and incidence**

In 2018, 4,655 people were diagnosed with TB in England, an 8.2% decline compared to 5,070 in 2017. The rate of TB reached an all-time low of 8.3 per 100,000 population in 2018 (Figure 1), and has been below the 10 per 100,000 WHO definition of a low incidence country since 2017. People born outside the UK accounted for 72% (3,283/4,580) of notifications in 2018, with a TB incidence rate of 39.0 per 100,000 population; this was 14-times greater than the rate among those born in the UK (2.8 per 100,000). There has been a decline in the number and rates of TB among both people born in the UK (number: -9.0%, rate -9.7%) and outside the UK (number: -8.1%, rate: -5.3%) between 2017 and 2018.

**Figure 1: Number of TB notifications and rates, England, 2000-2018**

![Graph showing number of TB notifications and rates from 2000 to 2018](image)

**Laboratory confirmation of TB**

In 2018, 61% (2,850/4,655) of people had their TB diagnosis confirmed by culture compared with 63% in 2017. A further 8% (383/4,655) had their diagnosis confirmed by an alternative positive laboratory result (microscopy, PCR or histology), and 31% (1,422/4,655) had no microbiological results available confirming their TB diagnosis, the notification being on clinical or radiological grounds only. A higher proportion of people with pulmonary TB had their diagnosis confirmed by culture compared with people with extra-pulmonary TB (74% versus 44%) and, as with previous years, culture confirmation
was lowest (31%; 47/151) among children (<15 years). Only 65% of people with pulmonary TB had a recorded sputum smear result, of which 56% were positive. As of the beginning of 2018, all new isolates of mycobacteria in England were examined by whole genome sequencing (WGS), providing species identification, drug resistance prediction and assessment of relatedness.

TB Transmission

The rate of TB in children born in the UK is used as a proxy for recent transmission. The rate in England was 1.2 per 100,000 in 2018 and demonstrates a continued decline in incidence (Figure 2). Work continues to develop measurable and reproducible TB transmission metrics incorporating whole genome sequencing data – aimed at tackling the burden of transmitted disease and working towards eliminating TB within England in compliance with WHO’s End TB Strategy.

Figure 2: Overall rate of TB in children (<15 years) born in the UK, England, 2000-2018

Delay from symptom onset to treatment start

In 2018, the median time between symptom onset and treatment start for people with pulmonary TB was 75 days. Almost 30% (692/2,373) of people with pulmonary TB experienced a delay of more than 4 months between symptom onset and treatment start; most notably for those aged 65 years or older. A higher proportion of people born in the UK (32%; 267/824) experienced a delay of more than 4 months compared to those born outside the UK (28%; 421/1,528).
TB outcomes in the drug sensitive cohort

The proportion of people with drug sensitive TB (with an expected treatment duration of less than 12 months) who completed treatment by 12 months in 2017 was essentially unchanged (84.7% in 2017 versus 85.0% in 2016) (Figure 3). Compared to 2016, there was a 2.8% decline in the proportion of children completing treatment within 12 months, following an annual improvement between 2011 and 2016. The difference in treatment completion by sex was greatest in those aged 65 years or older, with more females completing treatment by 12 months than males. The proportion of people with drug sensitive TB notified in 2017 who died (5.3%, 264/5,008) or were lost to follow-up (4.2%; 211/5,008) at the last reported outcome was comparable to previous years.

Figure 3: Outcomes at 12 months, by sex and age group, for people with drug sensitive TB with an expected treatment duration <12 months, England, 2017

<table>
<thead>
<tr>
<th>Age group</th>
<th>Female</th>
<th>Male</th>
<th>Female</th>
<th>Male</th>
<th>Female</th>
<th>Male</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Proportion of people (%)

- Treatment completed
- Died
- Still on treatment
- Lost to follow-up
- Treatment stopped
- Not evaluated

Excludes people in the drug resistant cohort and those with CNS, spinal, miliary or cryptic disseminated TB
Not evaluated includes unknown and transferred out

Drug resistant TB and outcomes in the drug resistant cohort

The proportion of people with initial isoniazid resistance without multi-drug resistant TB (MDR-TB) in 2018 increased to 6.6%, after remaining relatively consistent at an average of 5.4% (range: 4.8-5.9%) over the past 10 years (Figure 4). Drug resistance to pyrazinamide increased from 0.61% (21/3,465) to 3.66% (103/2,814) between 2016 and 2018, with most of these (81.6%) displaying monoresistance. There were fewer people with multi-drug /rifampicin resistant TB (MDR/RR-TB) in 2018 compared to 2017 (44 versus 54).
Of these, 4 had confirmed initial extensively-drug resistant TB. The number of people in the drug resistant cohort (confirmed or treated as MDR/RR-TB) decreased between 2017 and 2018 (62 versus 47). Of people in the 2016 drug resistant cohort, 65.2% (45/69) had completed treatment by 24 months, and 10.1% (7/69) remained lost to follow-up by the last recorded outcome.

**Figure 4: Number and proportion of people notified with TB with initial drug resistance, England, 2000-2018**

![Graph showing number and proportion of people notified with TB with initial drug resistance from 2000 to 2018.](image)

- People with culture confirmed TB with a result (DST or WGS) for at least isoniazid and rifampicin

**TB in under-served populations**

In 2018, 13.3% (539/4,062) of people diagnosed with TB who were aged 15 years or older had a social risk factor (SRF; current alcohol misuse, current or history of drug misuse, homelessness and/or imprisonment) – the highest proportion since data collection began in 2010. Of these, 77% (417/539) had pulmonary disease. Among people born in the UK, 20.7% (222/1,075) had a SRF compared to 10.6% (314/2,961) among those born outside the UK. The rate of TB in the most deprived 10% of the population was 16.6 per 100,000 compared to 3.0 per 100,000 in the least deprived 10%. MDR/RR-TB rates were similar for people with and without a SRF (1.2% versus 1.7%, respectively). Among people with drug sensitive TB, treatment completion was however lower for those who had a SRF (78.7%; 418/531), compared to those without a SRF (89.1%; 3,399/3,816). A higher proportion of people with a SRF died at their last recorded outcome compared to people without a SRF (6.2% versus 4.0%, respectively), and people with a SRF that were lost to follow-up (9.2%) was also 3-times greater than those without a SRF (3.1%).
TB-HIV co-infection and HIV testing among TB cases

In 2018, 2.7% (120/4,504) of people with TB were co-infected with HIV – the lowest proportion of co-infection since data became available in 2001 (Figure 5). The median age of people with TB-HIV co-infection increased from 34 to 46 years old between 2001 and 2018, respectively. Most of these people (81.7%; 94/115) were born outside the UK, most notably in sub-Saharan African countries (73.4%; 69/94).

Figure 5: Number and proportion of people with TB who have HIV co-infection, England, 2001-2018

![Figure 5: Number and proportion of people with TB who have HIV co-infection, England, 2001-2018](image)

\(^a\) Includes people with TB-HIV co-infection aged 15 years and older.

\(^b\) Proportion is calculated using the number of TB notifications with HIV co-infection plus the number who are un-notified with an MTBC isolate which matched to a person with HIV as the numerator, and the number of all TB notifications (with or without HIV co-infection) plus the number of un-notified TB isolates which matched to a person with HIV as the denominator.

BCG vaccination

There were 5 local authorities, all in London, that offered a universal BCG vaccination programme in 2018 to 2019, compared with 6 in 2017/18. Among the 5 areas, BCG coverage ranged from 36.8% in Brent to 68.9% in Newham. BCG vaccination coverage increased in 3 of the 5 areas (Brent, Ealing and Redbridge) compared to 2017 to 2018.

Latent TB infection testing and treatment

There was a 3.5% increase in the number of LTBI tests received between 2017 (15,343) and 2018 (15,883). The LTBI test positivity rate declined to 15.8% in 2018, compared to 17.0% in 2017 and 18.1% in 2016. A higher proportion of men tested
positive for LTBI than women across all age groups. People born in India and Pakistan have been the most represented groups since 2016. Overall, LTBI treatment completion has increased annually from 65.1% (358/550) in 2016 to 76.5% (349/456) in 2018.

**United Kingdom TB pre-entry screening programme**

In 2018, there were 304,234 screening episodes and 318 people with active TB were detected. The number of prevalent people notified with pulmonary TB in the UK (within 1 year of entry to the UK) from countries within the pre-entry scheme decreased from 154 in 2014 (when the implementation of the scheme was completed) to 69 in 2018.

**Conclusions**

TB notifications and rates in England have declined for the seventh consecutive year. Since 2014, the last year before the launch of the *Collaborative TB Strategy for England 2015 to 2020* [2], England has seen an almost 28% reduction in TB incidence. The number of TB notifications and rates in 2018 are the lowest recorded and England has been classified as a low incidence country by the WHO since 2017 (defined as a rate of less than 10 per 100,000 population). However, further work is needed to improve the outcomes for those most at risk of TB, reduce in-country TB transmission and maintain the decline in TB incidence and numbers. Key recommendations based on the findings of the ‘Tuberculosis in England: 2019 report’ are available in the full text version of the annual report. Wider recommendations on improving TB control in England are available in the Strategy.

Work is now focusing on preparing a 5-year TB Action Plan (2020 to 2025) to move England towards TB elimination. This TB Action Plan will build on the work carried out during the current Strategy period, refocus this to deliver any outstanding areas-for-action, consider new ideas, technologies and research and build on co-ordinated, multi-stakeholder working to deliver improved TB control across England. We must now work collectively to maintain and extend the downward trend in TB incidence and move England toward TB elimination by 2035.
References
